First Time Loading...

Seagen Inc
NASDAQ:SGEN

Watchlist Manager
Seagen Inc Logo
Seagen Inc
NASDAQ:SGEN
Watchlist
Price: 228.74 USD -0.07% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. [ Read More ]

The intrinsic value of one SGEN stock under the Base Case scenario is 143.78 USD. Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 37%.

Key Points:
SGEN Intrinsic Value
Base Case
143.78 USD
Overvaluation 37%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Seagen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Seagen Inc

Provide an overview of the primary business activities
of Seagen Inc.

What unique competitive advantages
does Seagen Inc hold over its rivals?

What risks and challenges
does Seagen Inc face in the near future?

Has there been any significant insider trading activity
in Seagen Inc recently?

Summarize the latest earnings call
of Seagen Inc.

What significant events have occurred
in Seagen Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Seagen Inc.

Provide P/S
for Seagen Inc.

Provide P/E
for Seagen Inc.

Provide P/OCF
for Seagen Inc.

Provide P/FCFE
for Seagen Inc.

Provide P/B
for Seagen Inc.

Provide EV/S
for Seagen Inc.

Provide EV/GP
for Seagen Inc.

Provide EV/EBITDA
for Seagen Inc.

Provide EV/EBIT
for Seagen Inc.

Provide EV/OCF
for Seagen Inc.

Provide EV/FCFF
for Seagen Inc.

Provide EV/IC
for Seagen Inc.

Show me price targets
for Seagen Inc made by professional analysts.

What are the Revenue projections
for Seagen Inc?

How accurate were the past Revenue estimates
for Seagen Inc?

What are the Net Income projections
for Seagen Inc?

How accurate were the past Net Income estimates
for Seagen Inc?

What are the EPS projections
for Seagen Inc?

How accurate were the past EPS estimates
for Seagen Inc?

What are the EBIT projections
for Seagen Inc?

How accurate were the past EBIT estimates
for Seagen Inc?

Compare the revenue forecasts
for Seagen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Seagen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Seagen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Seagen Inc compared to its peers.

Compare the P/E ratios
of Seagen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Seagen Inc with its peers.

Analyze the financial leverage
of Seagen Inc compared to its main competitors.

Show all profitability ratios
for Seagen Inc.

Provide ROE
for Seagen Inc.

Provide ROA
for Seagen Inc.

Provide ROIC
for Seagen Inc.

Provide ROCE
for Seagen Inc.

Provide Gross Margin
for Seagen Inc.

Provide Operating Margin
for Seagen Inc.

Provide Net Margin
for Seagen Inc.

Provide FCF Margin
for Seagen Inc.

Show all solvency ratios
for Seagen Inc.

Provide D/E Ratio
for Seagen Inc.

Provide D/A Ratio
for Seagen Inc.

Provide Interest Coverage Ratio
for Seagen Inc.

Provide Altman Z-Score Ratio
for Seagen Inc.

Provide Quick Ratio
for Seagen Inc.

Provide Current Ratio
for Seagen Inc.

Provide Cash Ratio
for Seagen Inc.

What is the historical Revenue growth
over the last 5 years for Seagen Inc?

What is the historical Net Income growth
over the last 5 years for Seagen Inc?

What is the current Free Cash Flow
of Seagen Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Seagen Inc.

Financials

Balance Sheet Decomposition
Seagen Inc

Current Assets 2.6B
Cash & Short-Term Investments 1.2B
Receivables 631.6m
Other Current Assets 683m
Non-Current Assets 1.1B
PP&E 487.7m
Intangibles 495m
Other Non-Current Assets 100m
Current Liabilities 954.7m
Accounts Payable 224.8m
Accrued Liabilities 729.9m
Non-Current Liabilities 129.1m
Other Non-Current Liabilities 129.1m
Efficiency

Earnings Waterfall
Seagen Inc

Revenue
2.3B USD
Cost of Revenue
-566.1m USD
Gross Profit
1.7B USD
Operating Expenses
-2.5B USD
Operating Income
-750.5m USD
Other Expenses
300k USD
Net Income
-750.2m USD

Free Cash Flow Analysis
Seagen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

SGEN Profitability Score
Profitability Due Diligence

Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
27/100
Profitability
Score

Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

SGEN Solvency Score
Solvency Due Diligence

Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
76/100
Solvency
Score

Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGEN Price Targets Summary
Seagen Inc

Wall Street analysts forecast SGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGEN is 229 USD .

Lowest
Price Target
Not Available
Average
Price Target
229 USD
0% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SGEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SGEN Price
Seagen Inc

1M 1M
-
6M 6M
+6%
1Y 1Y
+14%
3Y 3Y
+55%
5Y 5Y
+233%
10Y 10Y
+514%
Annual Price Range
228.74
52w Low
187.64
52w High
228.9
Price Metrics
Average Annual Return 35.81%
Standard Deviation of Annual Returns 37.12%
Max Drawdown -14%
Shares Statistics
Market Capitalization 43.1B USD
Shares Outstanding 188 663 008
Percentage of Shares Shorted 6.79%

SGEN Return Decomposition
Main factors of price return

What is price return decomposition?

SGEN News

Other Videos

Last Important Events
Seagen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Seagen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Seagen Inc Logo
Seagen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

43.1B USD

Dividend Yield

0%

Description

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 2,675 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The firm is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The firm also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The firm's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Contact

WASHINGTON
Bothell
21823 30Th Drive Se, Suite
+14255274000.0
https://www.seagen.com/

IPO

2001-03-07

Employees

2 675

Officers

Chief Financial Officer
Mr. Todd E. Simpson
Chief Legal Officer
Ms. Jean I. Liu J.D., M.S.
Exec. VP of Commercial U.S.
Mr. Charles R. Romp
Pres of R&D
Dr. Roger D. Dansey M.D.
CEO & Director
Mr. David R. Epstein B.Sc., M.B.A.
Chief Technical Officer
Dr. Vaughn B. Himes Ph.D.
Show More
Sr. VP of Investor Relations
Peggy Pinkston
VP of Corp. Communications
Mr. David Caouette
VP of Marketing
Mr. Matt Skelton
Exec. VP of HR
Mr. Christopher P. Pawlowicz
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGEN stock?

The intrinsic value of one SGEN stock under the Base Case scenario is 143.78 USD.

Is SGEN stock undervalued or overvalued?

Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 37%.